Stock Chart

VRDN

$33.20 +0.61%
Score: 65.4 BUY
LEAPs: SELL $40
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $40
Premium: $2.20
Expiry: Apr 17, 2026
Target: $39
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $33.93 - $38.76 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.88
Vol: 0.92x (vs SPY: 0.9x | vs QQQ: 1.0x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About VRDN - Viridian Therapeutics, Inc. Common Stock

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Key Statistics

Market Cap $3B

This VRDN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track VRDN's price movements with trendlines, gamma walls, and key support/resistance levels.